HUYA Bioscience International, an accelerator of the global development of China’s pharmaceutical innovations, has announced a joint venture with Tianjin Institute of Pharmaceutical Research (TIPR) to develop medical technologies and therapies, originating in both China and the western world, for global markets.

The joint venture, to be known as TIPR-HUYA Advancing Innovative Medicines (TIPR-HUYA-AIM), HUYA and TIPR will share equally in decision-making regarding product development and commercialization and focus initially on the fast-growing Chinese market.

HUYA and TIPR will identify and evaluate medical opportunities both within and outside China. The parties will utilize TIPR’s infrastructure and HUYA’s global network to accelerate the development of products for both the Chinese and global markets.

HUYA is one of the first companies to have recognized China’s potential to help meet the global need for new preclinical and clinical stage compounds. The company is focused on increasing the speed of development and value creation for China-sourced novel biopharmaceutical innovation in world-wide markets. HUYA has established a series of collaborations with universities and research institutes throughout China, and is jointly headquartered in Shanghai and San Diego, Calif.

TIPR is a pharmaceutical research institution in China. It is a wholly state-owned organization and provider of testing services for pharmaceutical, biotech, medical device, chemical and consumer products.